|
Pipeline Woes Strike Sanofi, Ipsen, Eisai: Nixed Applications, Clinical Holds and Trial Failures
Sanofi, Ipsen and Eisai all took pipeline hits this week, with late-stage setbacks including Sanofi’s withdrawal of marketing applications for a blood-clot drug, Ipsen’s clinical hold for an investigational hemophilia drug and Eisai’s failed breast cancer trial.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives